In 1948 Wong and Cox1 reported that aureomycin showed marked therapeutic activity for mice infected with psittacosis or with lymphogranuloma venereum viruses but that the drug was without effect against a B strain of influenza, canine distemper, rabies, Newcastle disease, Venezuelan equine encephalomyelitis and the MEF-1 strain of poliomyelitis. Largely on the basis of that report it has generally been assumed that aureomycin has no value in the treatment of human poliomyelitis. However, to the best of our knowledge no report has appeared on the clinical application of the drug, a subject of great interest to practicing physicians. It seemed to us worth while, therefore, to investigate the value of the drug in the early stages of the disease and to determine, if possible, whether it would have any influence on the clinical course. An investigation undertaken during the recent poliomyelitis epidemic formed the basis of this report.
APPELBAUM E, SAIGH R. AUREOMYCIN IN THE TREATMENT OF POLIOMYELITIS. JAMA. 1950;143(6):538–539. doi:10.1001/jama.1950.02910410024006